An analysis of national target groups for monovalent 2009 pandemic influenza vaccine and trivalent seasonal influenza vaccines in 2009-10 and 2010-11 by Ng, Sophia et al.
RESEARCH ARTICLE Open Access
An analysis of national target groups for
monovalent 2009 pandemic influenza vaccine
and trivalent seasonal influenza vaccines in 2009-
10 and 2010-11
Sophia Ng
1, Peng Wu
1, Hiroshi Nishiura
1,2, Dennis KM Ip
1, Esther ST Lee
1 and Benjamin J Cowling
1*
Abstract
Background: Vaccination is generally considered to be the best primary prevention measure against influenza
virus infection. Many countries encourage specific target groups of people to undertake vaccination, often with
financial subsidies or a priority list. To understand differential patterns of national target groups for influenza
vaccination before, during and after the 2009 influenza pandemic, we reviewed and analyzed the country-specific
policies in the corresponding time periods.
Methods: Information on prioritized groups targeted to receive seasonal and pandemic influenza vaccines was
derived from a multi-step internet search of official health department websites, press releases, media sources and
academic journal articles. We assessed the frequency and consistency of targeting 20 different groups within
populations which are associated with age, underlying medical conditions, role or occupations among different
countries and vaccines. Information on subsidies provided to specific target groups was also extracted.
Results: We analyzed target groups for 33 (seasonal 2009 and 2009-10 vaccines), 72 (monovalent pandemic 2009-
10 vaccine) and 34 (seasonal 2010 and 2010-11 vaccines) countries. In 2009-10, the elderly, those with chronic
illness and health care workers were common targets for the seasonal vaccine. Comparatively, the elderly, care
home residents and workers, animal contacts and close contacts were less frequently targeted to receive the
pandemic vaccine. Pregnant women, obese persons, essential community workers and health care workers,
however, were more commonly targeted. After the pandemic, pregnant women, obese persons, health care and
care home workers, and close contacts were more commonly targeted to receive the seasonal vaccine compared
to 2009-10, showing continued influence from the pandemic. Many of the countries provided free vaccines, partial
subsidies, reimbursements or national health insurance coverage to specific target groups and over one-third of
the countries offered universal subsidy regarding the pandemic vaccine. There was also some inconsistency
between countries in target groups.
Conclusions: Differences in target groups between countries may reflect variable objectives as well as
uncertainties regarding the transmission dynamics, severity and age-specific immunity against influenza viruses
before and after vaccination. Clarification on these points is essential to elucidate optimal and object-oriented
vaccination strategies.
Keywords: influenza, pandemic, seasonal, vaccine, target groups, subsidy
* Correspondence: bcowling@hku.hk
1School of Public Health, Li Ka Shing Faculty of Medicine, The University of
Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
Full list of author information is available at the end of the article
Ng et al. BMC Infectious Diseases 2011, 11:230
http://www.biomedcentral.com/1471-2334/11/230
© 2011 Ng et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Influenza vaccinations are effective in preventing con-
firmed influenza virus infections in infants [1], children
[2] and healthy adults [3]. However, the elderly are
thought to face the highest risk of severe influenza-asso-
ciated illness in interpandemic years [4,5], and influenza
vaccinations are often recommended to this group
although their effectiveness is uncertain [6]. In addition
to targeting specific age groups, health authorities also
commonly identify other target groups based on charac-
teristics such as underlying medical conditions or occu-
pations that may place people at higher risk of infection,
higher risk of severe disease if infected, or higher risk of
transmission to other vulnerable people. To facilitate
uptake in these target groups, priority access and subsi-
dies to receive influenza vaccines are often provided to
them.
Every year, the World Health Organization (WHO)
issues recommendations on influenza vaccine composi-
tion in February for the Northern Hemisphere, and Sep-
tember for the Southern Hemisphere. It usually takes
around 6 months after the recommendation meeting for
the vaccines to become available. In April 2009, a novel
influenza A(H1N1) virus emerged in North America
and rapidly spread around the world in the first influ-
enza pandemic of the 21
st century. Early in the pan-
demic it was reported that existing seasonal influenza
vaccinations including the 2009-10 trivalent seasonal
influenza vaccine were not likely to provide substantial
protection against the pandemic H1N1 (pH1N1) virus,
while the prevalence of pre-existing cross-reactive anti-
body against pH1N1, likely indicative of some degree of
protection against infection, was very low in most age
groups except the elderly [7]. Monovalent pH1N1 vac-
cines became available around the same time as the
2009-10 trivalent seasonal influenza vaccine towards the
end of 2009. The pH1N1 virus subsequently replaced
the seasonal A(H1N1) virus in the 2010 trivalent seaso-
nal influenza vaccine in the Southern Hemisphere, and
the 2010-11 trivalent seasonal influenza vaccine in the
Northern Hemisphere.
The pH1N1 virus appears to have displaced the pre-
pandemic seasonal influenza A(H1N1) viruses in global
circulation, while in some countries seasonal A(H3N2)
and B viruses also have continued to circulate. Influenza
vaccination remains the best primary preventive mea-
sure against these viruses. In addition to pre-pandemic
studies that took place prior to 2009 [8,9], the target
groups for influenza vaccinations before and during the
pandemic have been studied in Europe and the Ameri-
cas [10-12]. To investigate differential patterns of vacci-
nation targets and subsidy by different vaccines and
countries, we report and compare groups targeted in
different regions of the world to receive the monovalent
pH1N1 vaccine, the 2009 (Southern Hemisphere) and
2009-10 (Northern Hemisphere) seasonal vaccines
which included a seasonal A/Brisbane/59/2007(H1N1)-
like virus, and the post-pandemic seasonal vaccines in
2010 and 2010-11 that included a A/California/7/2009
(H1N1)-like (pH1N1) virus.
Methods
We grouped together the 2009 (Southern Hemisphere)
and 2009-10 (Northern Hemisphere) seasonal vaccines
as “S0910” vaccines since they both had the same virus
composition determined before the pandemic. Similarly
“S1011” vaccines referred to the 2010 (Southern Hemi-
sphere) and 2010-11 (Northern Hemisphere) seasonal
vaccines which had the same composition including the
pH1N1 virus. We used P0910 vaccine as the abbrevia-
tion for the 2009 monovalent pH1N1 vaccine. All these
vaccines were either adjuvanted or unadjuvanted,
including whole or split virions. Target groups were
identified as those that were explicitly listed as priori-
tized in each country to receive each of the vaccines
through a structured search of online resources. Since
P0910 competed for time compared to S0910 and
S1011, and because the total number of prioritized
groups varied substantially, the order of prioritization
was not considered in the present study. In addition we
searched for information on subsidies provided to speci-
fic target groups.
Search strategy
Information on the groups targeted to receive the seaso-
nal and pandemic influenza vaccines was obtained by a
multistep internet search performed from August 2010
through March 2011. Based on a list of 211 countries
[13], the official website of the national health authori-
ties were located using search terms < country name >
AND ("health ministry” OR “health department”)u s i n g
http://google.com, http://bing.com and http://yahoo.
com. A combination of search terms ("influenza” OR
“pandemic” OR “seasonal”) AND ("2009” OR “2010” OR
“2011”) AND ("vaccin*” OR “immunization” OR “immu-
nisation”) were then entered to the search engine
embedded in the official website. When no relevant
results were found, electronic press releases of the
national health authorities dated from July 2009 through
January 2011 were manually screened. Direct searches
using < country name > and the above combination of
search terms were performed if relevant information
was not retrievable from the official websites. We
regarded electronic news and academic journal articles
as acceptable secondary sources. The search terms were
translated into the official language of the country using
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appropriate results were not found using English search
terms. The information and the sources relevant to the
priority and subsidy groups were extracted into standar-
dized forms.
Analysis
After reviewing the reported target groups, we classified
them into three broad types, namely those defined by
age, those related to underlying medical conditions, and
those related to role or occupation. Regarding age-based
target groups, exact age brackets varied from country to
country. To facilitate comparison we categorized target
ages into 6 age groups: 0-5 years (pre-school children),
6-11 years (junior school children), 12-15 years (high
school children), 16-39 years (young adults), 40-64 years
(middle-aged adults) and 65 years or over (elderly).
We defined 4 groups relating to underlying medical
conditions. We defined pregnant (prg) to include
woman at any trimester of pregnancy, although some
countries targeted women only in the third (or second
and third) trimesters. Chronic illness (chr) included indi-
viduals with any chronic non-communicable and com-
municable conditions. This group also included
individuals with HIV/AIDS, immunosuppression and
pediatric conditions requiring long-term acetylsalicylic
acid therapy. Obesity (obe) was typically defined as hav-
ing body mass index of ≥ 40 kg/m
2. Disabled (dis) indi-
viduals included those with mental or physical
disabilities.
We defined 10 groups relating to specific roles or
occupations. Health care workers (hcw) were health pro-
fessionals and personnel involved with patient care in
hospital and ambulatory settings. Laboratory workers
(lab) were those with potential contact with specimens
containing or contaminated with influenza viruses. Close
contacts of high-risk groups (con) included those persons,
whether paid or unpaid, who have close contact with or
who take care of individuals at risk of severe illness if
infected, some of whom may not be able to receive
influenza vaccine themselves, in households, day care
centers or other institutions except for long-term care
facilities, hospital and ambulatory settings. Care home
residents (res) and workers (chw) included residents and
workers in long-term care facilities for the elderly and
other persons at risk of influenza infection. Teachers
(tch) were persons who provide formal education to
children in a school setting. Animal contacts (ani)
referred to those with direct contact with animals that
could be potential hosts of influenza viruses, in farms,
markets, abattoirs or during culling operations. Essential
community workers (ecw) referred to persons providing
services that are essential to the operation of the coun-
try, including key administrative personnel, police,
firemen, customs officer, military personnel, etc. Aborigi-
nals (abo) referred to indigenous persons and travelers
(trv) included frequent travelers, persons travelling to
areas with sustained transmission, and pilgrims.
After classifying target groups into the above cate-
gories, we visually presented target groups for each vac-
cine and compared patterns for different vaccines and
between countries. Subsidy groups were categorized
similarly as the target groups with addition of the finan-
cial need group for whose low-income cannot afford the
vaccine and universal for countries which provided sub-
sidy for all. The proportion of observed agreement (by
different vaccines or between countries) was investigated
to characterize targeting patterns of prioritization and
subsidy. Moreover, as an objective measurement of con-
sistency in each prioritized group between vaccines and
between countries, we employed a multiple-rater agree-
ment coefficient, the AC1 statistic [14]. AC1 is known as
a new measurement of consistency, replacing unstable
kappa coefficient due to the paradox-resistant robust-
ness [14]. The AC1 statistic can take any value from -1
to 1, with 1 indicating full consistency, 0 absence of
consistency (the degree of agreement expected by
chance), and negative values indicating inconsistency or
disagreement. To analyze differences in target groups,
AC1 was computed for each pair of two different vac-
cines, and between countries for each vaccine. The 95%
confidence intervals for the AC1 statistics were obtained
using bootstrap resampling with 1,000 resamples. We
used c
2 and Fisher’se x a c tt e s t st oc o m p a r et a r g e t
groups for the P0910 vaccine between countries that did
or did not receive donated vaccines via the WHO.
Results
Recommendations on the priority and subsidy groups
were found for 72 and 57 countries relevant to the
P0910 vaccine; 33 and 20 countries for the S0910 vac-
cine; 34 and 28 countries for the S1011 vaccine. The
majority of the information was retrieved from national
health authority websites, and full details are provided
in Additional File 1. The countries with retrieved infor-
mation on vaccination were distributed in Africa, the
Americas, Asia and the Pacific, and Europe. Sixteen of
these countries received donations of monovalent
pH1N1 vaccine via the WHO [15]. Subsidy for vaccina-
tion was provided in various ways in different countries.
Some of the countries provided the vaccine for free
without any charge to the recipient, or at a cost in
which part of the vaccine and administration fee were
subsidized. In several places, the vaccines were covered
in the national health insurance programs for specific
risk groups (Figures 1 and 2, Additional File 1). The
definition of chronic illness varied between countries.
The detailed lists of health conditions included by each
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China ●●● ●●● ● ● ●●
Hong Kong ●● ● ● ●●
India ●●
Japan ●●● ● ●● ● ●
Korea ●●● ●●
Malaysia ●●
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New Zealand ●●● ●
Philippines ●● ● ● ● ●
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Sri Lanka ●● ●● ●
Taiwan ●●●● ●● ●
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trv res n/f fin all
Argentina ● ●●● ●●
Bahamas ●● ● ● ●
Belize ●●
Bolivia ●●● ● ●
Brazil ●● ● ● ● ●
Canada ● ●● ●●● ● ●
Chile ●● ● ● ●
Colombia ●● ●●
Costa Rica ●●● ●●
Cuba ●● ●●●●● ● ●
Dominican Republic ●● ●
Ecuador ●●● ● ●●
El Salvador ● ●●● ● ●
Guatemala ● ● ●●●
Guyana ●● ● ●
Honduran Republic  ●●●● ●●● ● ●
Jamaica ●●● ● ●
Mexico ● ●●● ● ●
Nicaragua ●● ●
Panama ● ●●● ● ● ●
Paraguay ● ● ●●● ● ●
Suriname ●●●●● ●● ● ●●
USA ●●●● ●● ●●●
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Figure 1 Groups prioritized to receive the 2009 and 2009-10 seasonal trivalent influenza vaccine (black square), 2009 monovalent
pandemic influenza vaccine (black open circle), and 2010 and 2010-11 seasonal trivalent influenza vaccine (gray square) in countries
located in Asia and the Pacific, and the Americas. Groups subsidized to receive the vaccine for free (f), at a cost with partial subsidy (p), with
reimbursable cost (r) or insured by national health insurance (i) were also denoted. Target group abbreviations: 0-5 (0-5 years), 6-11 (6-11 years),
12-15 (12-15 years), 16-39 (16-39 years), 40-64 (40-64 years), 65+ (65 years or over), prg (pregnant), chr (chronic illness, obe (obesity), dis (disabled),
hcw (health care workers), lab (laboratory workers), con (close contacts), res (care home residents), chw (care home workers), tch (teachers), ani
(animal contacts), ecw (essential community workers), abo (aboriginals), trv (travelers).
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Croatia ●●● ●
Czech Republic ●● ● ● ● ●
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Estonia ● ●●● ● ● ●
Finland ●●●● ●● ● ●
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Malta ●● ●
Netherlands ●● ● ●● ●
Norway ●●● ● ●
Poland ●● ● ●
Portugal ●● ●●● ● ● ●
Romania ●●● ●
Slovakia ●● ● ● ●
Slovenia ●●● ●● ●
Spain ●●● ● ● ●
Switzerland ●● ● ●
Turkey ●● ● ●
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Algeria ●● ● ● ● ●
Botswana ●●●● ●● ● ●
Ethiopia ● ●●● ●
Madagascar ●●
Morocco ●●
Sierra Leone ●● ● ●
South Africa ●● ●
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Figure 2 Groups prioritized to receive the 2009 and 2009-10 seasonal trivalent influenza vaccine (black square), 2009 monovalent
pandemic influenza vaccine (black open circle), and 2010 and 2010-11 seasonal trivalent influenza vaccine (gray square) in countries
located in Europe and Africa. Groups subsidized to receive the vaccine for free (f), at a cost with partial subsidy (p), with reimbursable cost (r)
or insured by national health insurance (i) were also denoted. Abbreviations for age, underlying medical conditions, role and occupation are the
same as those employed in Figure 1.
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Page 5 of 11country are shown in Additional File 1. Priority and
subsidy groups in individual countries in Asia, the Paci-
fic and the Americas are shown in Figure 1, and those
for Europe and Africa are shown in Figure 2. To allow
for comparison of target groups between vaccines, Fig-
ure 3 shows the proportions of observed agreement for
each target group among 31 countries where informa-
tion on all 3 vaccines was identified (the 31 countries
included in Figure 3 corresponded to those without “n/
f” indicated in Figure 1 and 2). Figures 4 and 5 compare
the consistency of target groups between vaccines and
between countries using AC1 statistics, respectively.
Target groups for the 2009 and 2009-10 seasonal vaccine
Almost all the countries prioritized the elderly (97%)
and those with chronic illness (91%) to receive the
S0910 vaccine (Figures 1 and 2, Table 1). Health care
workers (70%) and care home residents (52%) were tar-
g e t e db yo v e rh a l fo ft h ec o u n t r i e s .P r e g n a n tw o m e n
were not consistently targeted (46%) and very few
(a) Age
Seasonal
2009−10
Pandemic
2009−10
Seasonal
2010−11
0−5y 35% 35% 0−5y
6−11y 6% 6% 6−11y 12−15y 3% 3% 12−15y
16−39y 3% 0% 16−39y
40−64y 19%
13% 40−64y
>65y 97%
87% >65y
(b) Medical conditions
Seasonal
2009−10
Pandemic
2009−10
Seasonal
2010−11
prg 45%
65% prg
chr 97%
94% chr
obe 3%
29% obe
dis 6%
3% dis
(c) Role / occupation
Seasonal
2009−10
Pandemic
2009−10
Seasonal
2010−11
hcw 71%
77% hcw
lab 13%
6% lab
con 39%
52% con
tch 6% 6% tch
chw 35%
42% chw
ani 39%
32% ani
ecw 26%
23% ecw
abo 6%
10% abo trv 10%
3% trv
res 55%
65% res
Figure 3 The frequency of risk groups prioritized to receive the seasonal trivalent influenza vaccine, 2009 monovalent pandemic
influenza vaccine, and 2010 and 2010-11 trivalent seasonal influenza vaccine in 31 countries in which the target group information
were found for all 3 vaccines. Abbreviations for age, underlying medical conditions, role and occupation are the same as those employed in
Figure 1. White grid lines are included at 10% intervals.
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Figure 4 The pairwise consistency of target groups between the 2009 and 2009-10 trivalent seasonal influenza vaccine, the 2009-10
monovalent pandemic influenza vaccine and the 2010 and 2010-11 trivalent seasonal influenza vaccines. Points show the estimates of
the multiple-rater agreement AC1 statistics, lines show the bootstrap-based 95% confidence intervals. Abbreviations for age, underlying medical
conditions, role and occupation are the same as those employed in Figure 1.
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Page 6 of 11countries targeted the obese (3%). Like the priority
groups, many countries provided subsidy to the elderly
(90%), those with chronic illnesses (80%), health care
workers (45%) and care home residents (45%) to receive
the vaccine. Pregnant women were not always subsi-
dized (30%). Countries included in our study were not
as consistent in including in target groups children aged
0-5 years, pregnant women, close contacts, animal con-
tacts, care home residents and workers (Figure 5).
Target groups for the 2009 monovalent pH1N1 vaccine
Pregnant women, health carew o r k e r sa n dt h o s ew i t h
chronic illnesses were commonly targeted (~90%).
Around 50% of the countries targeted pre-school chil-
dren, one-fifth to one-fourth for older children, obese
persons and close contacts. Compared to the S0910
vaccine, elderly, care home residents and workers,
close contacts, and animal contacts were less com-
monly targeted to receive P0910 vaccine (Figures 1, 2
and 3, Table 1). More commonly targeted groups
included children of all age, young adults, pregnant
women, obese persons, essential community workers
and health care workers. The low AC1 values among
these groups indicate that the target groups between
two vaccines were inconsistent (Figure 4). The AC1
value was lowest in the comparison for the elderly
group between P0910 and either seasonal vaccine. The
AC1 values of these two combinations (i.e. compari-
sons between pandemic and either of seasonal vac-
cines) for pregnant women and care home residents
were also very low and close to 0. Among countries
that received donation of P0910 vaccine via the WHO,
all of them had targeted pregnant women (100%), and
most of them had recommended those with chronic
illnesses (94%) and health care workers (94%) to
receive vaccination (Additional File 2). Within these
countries, pre-school children were the most com-
monly targeted age group.
Unlike the S0910 vaccine, the elderly (16%), care
home residents (2%) and workers (5%) were not often
subsidized to receive the P0910 vaccine. Contrarily, chil-
dren especially those aged below 5 years (32%) and
pregnant women (46%) were commonly subsidized.
Similar to the S0910 vaccine, many countries subsidized
those with chronic illnesses (54%) and health care work-
ers (47%) to receive the P0910 vaccine. Young adults
(7%) and the obese (12%) had not been subsidized prior
to the P0910 vaccine. While most of the countries only
offered subsidy to the targeted groups for the seasonal
vaccines, 21/57 countries provided universal subsidy to
their population for the pandemic one. The countries
showed higher consistency in determining whether to
target the middle age, pregnant women, health care
workers, care home residents and workers, animal con-
tacts and travelers to receive the P0910 compared to the
seasonal vaccines (Figure 5). There was less consistency
in targeting the younger age groups, the elderly and
obese persons.
Target groups for the 2010 and 2010-11 trivalent
seasonal vaccine
The relative frequencies of groups prioritized for the
S1011 vaccine were generally similar to the S0910 vac-
cine (Figures 1, 2 and 3, Table 1) with several notable
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Figure 5 The consistency of target groups between the 31 countries in which the target group information were found for all 3
vaccines. Points show the estimates of the multiple-rater agreement AC1 statistics, lines show the bootstrap-based 95% confidence intervals.
Abbreviations for age, underlying medical conditions, role and occupation are the same as those employed in Figure 1.
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Page 7 of 11changes. One particular change following the pandemic
was that pregnant women and obese persons were more
commonly targeted for the S1011 vaccine than they had
been for the S0910 vaccine. Interestingly, close contacts,
health care workers and care home workers were also
more frequently targeted for the seasonal vaccine after
the pandemic. As mentioned above, some groups
including the elderly, care home residents, and animal
contacts were less commonly targeted for the P0910
vaccine compared to the S0910 vaccine. In 2010-11,
these groups continued to be targeted as in the previous
year for the S0910 vaccine. This was also reflected by
the higher AC1 values when S1011 is compared against
S0910 vaccine (Figure 4). The pandemic also appeared
to have reduced the consistency to target the elderly
and obese persons for S1011 vaccine among different
countries (Figure 5).
Like the S0910 vaccine, the elderly (82%), those with
chronic illnesses (79%), health care workers (50%) and
care home residents (39%) were frequently subsidized to
receive the S1011 vaccine. Pregnant women (57%) and
the obese (25%) continued to be subsidized after becom-
ing new target groups for the P0910 vaccine. Close con-
tacts (36%) not only were more frequently prioritized,
b u tt h e yw e r ea l s os u b s i d i z e db ym a n yc o u n t r i e st o
receive the S1011 vaccine.
Table 1 Frequency of target groups prioritized and subsidized to receive the pandemic 2009-10, seasonal 2009 &
2009-10, and seasonal 2010 & 2010-11 vaccines
Seasonal 2009-10 vaccine Pandemic 2009-10 vaccine Seasonal 2010-11 vaccine
Priority Subsidy Priority Subsidy Priority Subsidy
n (%) n (%) n (%) n (%) n (%) n (%)
Countries 33 - 20 - 72 - 57 - 34 - 28 -
Age (year)
0-5 13 (39.4) 5 (25.0) 33 (45.8) 18 (31.6) 13 (38.2) 8 (28.6)
6-11 2 (6.1) 3 (15.0) 17 (23.6) 9 (15.8) 2 (5.9) 2 (7.1)
12-15 1 (3.0) 1 (5.0) 15 (20.8) 5 (8.8) 1 (2.9) 1 (3.6)
16-39 1 (3.0) 0 (0.0) 10 (13.9) 4 (7.0) 0 (0.0) 0 (0.0)
40-64 6 (18.2) 1 (5.0) 3 (4.2) 0 (0.0) 4 (11.8) 2 (7.1)
65+ 32 (97.0) 18 (90.0) 12 (16.7) 9 (15.5) 30 (88.2) 23 (82.1)
Underlying medical conditions
Chronic illness 30 (90.9) 16 (80.0) 63 (87.5) 31 (54.4) 31 (91.2) 22 (78.6)
Pregnant 15 (45.5) 6 (30.0) 65 (90.3) 26 (45.6) 22 (64.7) 16 (57.1)
Disabled 2 (6.1) 1 (5.0) 1 (1.4) 1 (1.8) 1 (2.9) 2 (7.1)
Obese 1 (3.0) 0 (0.0) 20 (27.8) 7 (12.3) 9 (26.5) 7 (25.0)
Role & occupation
Health care worker 23 (69.7) 9 (45.0) 66 (91.7) 27 (47.4) 25 (73.5) 14 (50.0)
Care home resident 17 (51.5) 9 (45.0) 1 (1.4) 1 (1.8) 20 (58.8) 11 (39.3)
Animal contact 13 (39.4) 5 (25.0) 2 (2.8) 2 (3.5) 10 (29.4) 8 (28.6)
Close contact 12 (36.4) 5 (25.0) 16 (22.2) 5 (8.8) 18 (52.9) 10 (35.7)
Care home worker 11 (33.3) 5 (25.0) 11 (15.3) 5 (5.3) 13 (38.2) 6 (21.4)
Essential community service 9 (27.3) 4 (20.0) 27 (37.5) 13 (22.8) 7 (20.6) 5 (17.9)
Laboratory worker 4 (12.1) 1 (5.0) 7 (9.7) 1 (1.8) 2 (5.9) 1 (3.6)
Traveler 3 (9.1) 1 (5.0) 1 (1.4) 0 (0.0) 1 (2.9) 1 (3.6)
Teacher 2 (6.1) 0 (0.0) 5 (6.9) 2 (3.5) 3 (8.8) 2 (7.1)
Aboriginal 2 (6.1) 1 (5.0) 5 (6.9) 0 (0.0) 3 (8.8) 1 (3.6)
Financial need* - - 2 (10.0) - - 3 (5.3) - - 2 (7.1)
Universal
† - - 2 (10.0) - - 21 (36.8) - - 3 (10.7)
* financial need group for whose low-income cannot afford the vaccine.
† universal for countries which provided subsidy for all.
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There were some notable differences between groups
targeted for the 2009-10 pandemic and seasonal influ-
enza vaccines, and substantial differences in target
groups between countries. The greatest inconsistency in
target groups was seen in comparisons between S0910
and P0910. Some groups targeted for the pandemic vac-
cine more commonly than for the 2009-10 seasonal vac-
cine, including pregnant women and obese persons, and
health care workers were subsequently more commonly
targeted for the 2010-11 post-pandemic seasonal vac-
cine. Subsidies to increase vaccine uptake were available
to target groups in many countries by either providing
the vaccine for free, at a subsidized cost or through
national health insurance (Figures 1 and 2).
Before further discussing the patterns in target
groups, two important issues should be noted: (A) the
social and political backgrounds of policy decisions to
prioritize certain groups for P0910 are likely to differ
from those for seasonal vaccines and (B) the ‘best’ or
‘optimal’ strategy to achieve certain public health
objectives has yet to be fully clarified in the context of
including or excluding certain groups for prioritization.
A sf o r( A ) ,c o m p a r e dt os e a s o n a lv a c c i n e s ,p u b l i c
health decision of prioritized groups for P0910 may be
more associated with maintaining social security dur-
ing emergency vaccination and avoiding any confusion
that could arise from ‘first come, first served’ basis
among the public [8]. On the other hand, policymaking
of seasonal vaccines is unlikely to face needs to give
rapid decisions for implementing emergency vaccina-
tion programmes and to maintain social security, and
rather, target groups of seasonal vaccines may some-
times reflect the results of surveys of public demands
among the potential target groups and may also take
into account aspects of cost-benefit and cost-effective-
ness. With respect to (B), various studies including
modeling exercises considered optimal vaccination
strategies [16-18] but those exercises have not allowed
full clarification of all target groups. It should be
emphasized that the limitations of modeling studies
and inconsistency in target groups (as seen in the pre-
sent study) may be attributable to non-uniform public
health objectives of vaccination, such as reducing peak
hospital burden versus reducing overall mortality, as
well as uncertainties with respect to the transmission
dynamics, severity and age-specific immunity against
influenza viruses before and after vaccination. The
objective of this study has been not to criticize certain
choices of target groups, but to explore to what extent
target groups are similar between countries, or even
within countries from year to year and between the
seasonal and pandemic vaccines.
Some inconsistent patterns were seen between pan-
demic and seasonal vaccines in targeting certain age
groups, those with underlying medical conditions and
those with occupations associated with higher risk. First,
mathematical modeling studies have shown that achiev-
ing high vaccination coverage among school-age children
could substantially elevate herd immunity and protect
other risk groups (including elderly and those with
underlying diseases) by means of a ‘transmission-limiting’
strategy [17-20]. Nevertheless, many countries experi-
enced substantial attack rates in children before vaccines
became available [21], and in such an instance (e.g. after
observing epidemic peak), effectiveness of transmission-
limiting strategy tends to be minimal [19,22]. While
school-age children were targeted for the P0910 vaccine
in some countries, most countries included in our review
adopted a morbidity-limiting strategy and targeted
groups at high risk of severe disease (Figures 1 and 2).
Vaccine effectiveness in the elderly remains uncertain [6]
but the elderly are commonly targeted to receive inter-
pandemic influenza vaccine because of their high risk of
severe disease [4,5]. However, early seroepidemiological
studies in 2009 suggested that the elderly may be pro-
tected against infection [23], and few countries included
elderly in the target groups for the P0910 vaccine (Figure
3 and Table 1).
Second, with regard to underlying medical conditions,
pregnant and postpartum women appeared to be at
higher risk of severe disease if infected from the early
stages of the pandemic [24-27] and many countries
prioritized this group to receive the vaccine when it
became available. Whereas pregnant women were less
commonly targeted for seasonal influenza vaccination
before the pandemic, evidence of an increased risk of
severe influenza had already been observed in pregnant
women before 2009 [28-30]. Influenced by the 2009
pandemic, 22/34 countries targeted this group for S1011
vaccine (Figures 1 and 2, Table 1). Other than pregnant
women, a number of studies during the pandemic found
obesity to be a risk factor for hospitalization and death
[26,31-33], and some countries incorporated obese indi-
viduals into the target groups for the P0910 vaccine and
again retained them in the target groups for the post-
pandemic S1011 vaccine (Figures 1 and 2, Table 1).
Third, regarding roles and occupations, health care
workers were targeted for both pandemic and seasonal
influenza vaccines by many countries and they have
been increasingly targeted during and after the course of
the pandemic (Figures 1, 2 and 3, Table 1), although
t h e ym a yn o tn e c e s s a r i l yf a c eh i g h e rr i s ko fi n f e c t i o n
due to occupational exposures [34,35] and the issue of
mandatory vaccination in this group remains controver-
sial [36,37]. Workers in long term residential care
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vaccine compared to the seasonal vaccines, perhaps
because of the apparent low risk of pH1N1 in the
elderly [7,21]. Animal contacts might have been less
commonly targeted merely because of displacement by
other risk groups as P0910 vaccine was initially expected
to be scarce. Later they were more commonly targeted
for the S1011 influenza vaccine which included the pan-
demic strain.
A few limitations should be discussed. We were not
able to find information on priority groups in many
countries, and thus, the data included in our review may
not sufficiently represent the worldwide patterns in tar-
get groups. In addition, information available online
could differ from what was actually implemented, even
though most of the information included in our study
was from official government websites. Potentially lower
quality sources were excluded by limiting our search to
official webpage of the government, news or academic
journal articles. Future studies of influenza vaccine poli-
cies could consider a survey-based approach interview-
ing a representative health official from each country.
Actual vaccine uptake or influenza-associated morbidity
should also be investigated in relation to the policy deci-
sions of target groups when relevant data are available
as part of policy evaluations. There were also within
country variations; e.g. recommendations on target
groups in Canada and the United States differed
between states. In these situations, the federal recom-
mendations were used to reflect the central policy, but
more detailed investigation of the heterogeneity in target
groups between states or regions could be a topic for
further research especially for a within-country policy
evaluation.
Conclusions
Countries selected different target groups for the pan-
demic vaccine and seasonal vaccines before and after the
pandemic. Our results also highlighted substantial incon-
sistencies between individual countries for each vaccine.
Although inconsistency between vaccines partly repre-
sents the influence of differential social backgrounds of
policymaking, the inconsistencies essentially highlight
differential public health objectives of vaccination and
the ongoing uncertainty with respect to the transmission
dynamics, severity profile and immunology of influenza.
Improving our understanding of influenza epidemiology
must help optimize vaccination strategies in the future.
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